retatrutide triple agonist glp-1 gip glucagon phase 3 2025 is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Retatrutide 10mg Triple Agonist |

Users who sign up for Noom and qualify for medication will now be offered the option of joining the new program

Additionally, the study assessed weight and metabolic responses, finding that efinopegdutides tolerability was similar to that of semaglutide, although certain gastrointestinal side effects were more common

(for more details click here) Kidney bladder and prostate ultrasound Estimated prostate size/volume Post void residual volume remaining urine volume in bladder after voiding Rule out bladder stones and other bladder abnormalities Bladder diary a diary recording the volume of urine passed and fluids consumed over a 24-48hour period Flow rate/bladder scan performed in the office at GM Urology Cystoscopy to look for other causes of symptoms and assess the shape of the prostate Urodynamics may be used in selected men with LUTS to help dictate treatment How is BPH treated

Pharmacists are filling prescriptions for GLP-1 medications like Ozempic and Wegovy more than ever before